[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336792-105":59,"doc-detail-336792-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","biological-barriers-for-drug-delivery-and-development-of-innovative-therapeutic-approaches-in-hiv-pancreatic-cancer-and-hemophilia-ab-review","Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B - Review","","Biological barriers remain a major obstacle to developing innovative therapeutics. Drugs often must overcome multiple barriers—spanning organ, tissue, and cellular compartments—to become effective in a defined intracellular location. Human barriers include diverse protective and obstructive layers, from outer plasma membranes and endolysosomal machinery to the nuclear envelope. Clinicians now access small molecules, biologics, nucleic-acid therapeutics, and antibody-drug conjugates, including emerging gene and mRNA-based strategies, prompting rapid innovation across disease areas.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/biological-barriers-for-drug-delivery-and-development-of-innovative-therapeutic-approaches-in-hiv-pancreatic-cancer-and-hemophilia-ab-review/336792/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/biological-barriers-for-drug-delivery-and-development-of-innovative-therapeutic-approaches-in-hiv-pancreatic-cancer-and-hemophilia-ab-review/336792.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes biological barriers a central challenge in drug delivery?","Question",{"text":112,"@type":113},"Biological barriers can block drugs at multiple levels, including tissue/organ barriers and cellular structures such as membranes, endosomal compartments, and the nuclear envelope.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which therapies and drug categories does the review discuss as overcoming barriers?",{"text":117,"@type":113},"It covers chemically synthesized small molecules, biologics like recombinant proteins, nucleic-acid-based therapeutics, antibody-drug conjugates, and modern viral-vector-mediated gene therapy, including examples tied to siRNAs and hemophilia treatments.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review structure its focus across diseases?",{"text":121,"@type":113},"It examines three clinically impactful disease entities—HIV (AIDS), pancreatic carcinoma, and hemophilia A/B—to highlight overarching principles of biological barriers and promising cross-barrier therapeutic approaches.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336792,1790917802,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","pharmaceutics  \nReview  \nBiological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B  \nEmre Basar 1, *,†, Henry Mead 2,†, Bennett Shum 3,4, Ingrid Rauter 5, Cihan Ay 6, Adriane Skaletz-Rorowski 1 and Norbert H. Brockmeyer 1, *  \nCitation: Basar, E.; Mead, H.; Shum, B.; Rauter, I.; Ay, C.; Skaletz-Rorowski, A.; Brockmeyer, N.H. Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B. Pharmaceutics 2024, 16, 1207 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)pharmaceutics16091207  \nAcademic Editors: Franciska Erd˝o, Heidi Kidron and Anna Soba ´nska  \nReceived: 26 July 2024  \nRevised: 6 September 2024  \nAccepted: 7 September 2024  \nPublished: 13 September 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 WIR—Walk In Ruhr, Center for Sexual Health & Medicine, Department of Dermatology, Venerology and Allergology, Ruhr-University Bochum, 44787 Bochum, Germany; [adriane.skaletz-rorowski@klinikum-bochum.de](adriane.skaletz-rorowski@klinikum-bochum.de)  \n2 BioMarin LLC, San Rafael, CA 94901, USA  \n3 GenePath LLC, Sydney, NSW 2067, Australia  \n4 EMBL Australia Node in Single Molecule Science, School of Medical Sciences, University of NSW, Sydney, NSW 2052, Australia  \n5 Vaccentis AG, 8001 Zurich, Switzerland  \n6 Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria  \n* Correspondence: [emrebasar2015@gmail.com](emrebasar2015@gmail.com) (E.B.); [nhb@nbrockmeyer.de](nhb@nbrockmeyer.de) (N.H.B.)† These authors contributed equally to this work.  \nAbstract: Biological barriers remain a major obstacle for the development of innovative therapeutics. Depending on a disease’s pathophysiology, the involved tissues, cell populations, and cellular components, drugs often have to overcome several biological barriers to reach their target cells and become effective in a specific cellular compartment. Human biological barriers are incredibly diverse and include multiple layers of protection and obstruction. Importantly, biological barriers are not only found at the organ/tissue level, but also include cellular structures such as the outer plasma membrane, the endolysosomal machinery, and the nuclear envelope. Nowadays, clinicians have access to a broad arsenal of therapeutics ranging from chemically synthesized small molecules, biologicals including recombinant proteins (such as monoclonal antibodies and hormones), nucleicacid-based therapeutics, and antibody-drug conjugates (ADCs), to modern viral-vector-mediated gene therapy. In the past decade, the therapeutic landscape has been changing rapidly, giving rise to a multitude of innovative therapy approaches. In 2018, the FDA approval of patisiran paved the way for small interfering RNAs (siRNAs) to become a novel class of nucleic-acid-based therapeutics, which—upon effective drug delivery to their target cells—allow to elegantly regulate the post-transcriptional gene expression. The recent approvals of valoctocogene roxaparvovec and etranacogene dezaparvovec for the treatment of hemophilia A and B, respectively, mark the breakthrough of viral-vector-based gene therapy as a new tool to cure disease. A multitude of highly innovative medicines and drug delivery methods including mRNA-based cancer vaccines and exosome-targeted therapy is on the verge of entering the market and changing the treatment landscape for a broad range of conditions. In this review, we provide insights into three different disease entities, which are clinical","cbCaieoKI5fCTrFs","https://ap.wps.com/l/cbCaieoKI5fCTrFs","pdf",3408804,32,"English","# 1. Introduction\n## Biological barriers and key delivery obstacles\n## Cellular and molecular barriers\n# Keywords and scope\n## Disease areas covered in the review\n## Therapeutic approaches and delivery strategies","[{\"question\":\"What makes biological barriers a central challenge in drug delivery?\",\"answer\":\"Biological barriers can block drugs at multiple levels, including tissue/organ barriers and cellular structures such as membranes, endosomal compartments, and the nuclear envelope.\"},{\"question\":\"Which therapies and drug categories does the review discuss as overcoming barriers?\",\"answer\":\"It covers chemically synthesized small molecules, biologics like recombinant proteins, nucleic-acid-based therapeutics, antibody-drug conjugates, and modern viral-vector-mediated gene therapy, including examples tied to siRNAs and hemophilia treatments.\"},{\"question\":\"How does the review structure its focus across diseases?\",\"answer\":\"It examines three clinically impactful disease entities—HIV (AIDS), pancreatic carcinoma, and hemophilia A/B—to highlight overarching principles of biological barriers and promising cross-barrier therapeutic approaches.\"}]","Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B - Review | PDF",1790016631,81,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecb0555f88da5f8bda87608bc1ac1a37.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fbf8e1b38ee7bf7603636b14aa9331f.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40a7d09d0f5e886a20262137e61b5b52.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbeed7d1a3d6ba136dfcfe67d582bb2b.webp",980,1385]